Citations

Clear

948 citation(s) found for "Li, Bryan".

Shape-sensing robotic-assisted bronchoscopy with integrated mobile cone-beam CT for small nodules: results from the prospective multicentre CONFIRM study
Husta, Bryan C, Cheng, George Z. , Batra, Hitesh , Reisenauer, J., Bartek, William, Kalchiem‐Dekel, Or , Zouk, Aline, Patel, Niral, Chawla, Mohit, Eapen, George A. , Jiménez, C. Delgado, Lee, R. J., Bott, Matthew J. , Oh, Scott , Casal, Roberto F, Casal, Roberto , Reisenauer, Janani , Zouk, Aline N., Patel, Niral M. , Chawla, Mohit , Casal, Roberto F.

Mayo Clinic

Thorax | February 16, 2026 | Volume: 81 | Issue: 3 | Pages: 267-275

10.1136/thorax-2025-223272 | PMID 41698810 Get It

Background The use of 3D imaging with navigation bronchoscopy has increased with the introduction of mobile cone-beam CT (mCBCT). Shape-sensing robotic-assisted bronchoscopy (ssRAB) integrated with mCBCT has been introduced to correct for CT to body divergence (CT-BD) during the biopsy of peripheral pulmonary nodules (PPNs). Methods Prospective observational multicentre study, enrolling patients with a PPN of ≤20 mm suspicious for malignancy, assessing tool-in-lesion (TIL), diagnostic yield, sensitivity for malignancy and incidence of pneumothorax or airway bleeding. Non-malignant index biopsies were followed for 12 months. Descriptive statistics are reported for all variables along with 95% CI for primary endpoints. Results 155 consecutive patients were enrolled at six centres. Median nodule size was 14.0 mm (IQR 11.0–17.0), with 54.8% of nodules (85/155) in the upper lobes, 25.8% (40/155) with CT bronchus sign present and median distance to the nearest pleural surface of 8.2 mm (IQR 1.8–20.0). TIL was achieved in 154/155 (99.4%, 95% CI 96.5 to 100.0) procedures. A median of two (IQR 1–3) mCBCT spins were performed, with median dose area product of 25.7 Gy · cm 2 (IQR 11.0–46.7). Diagnostic yield per the American Thoracic Society/American College of Chest Physicians (ATC/ACCP) definition was 89.0% (n=138/155; 95% CI 83.0 to 93.5) and sensitivity for malignancy was 91.5% (95% CI 86.4 to 96.5). No pneumothorax (0%, 95% CI 0.0 to 2.4) and two Nashville Grade three bleeding events were reported (1.3%, 95% CI 0.2 to 4.6). Interpretation The first prospective multicentre study of integrated ssRAB and mCBCT for small peripheral nodules resulted in diagnostic outcomes similar to those reported for transthoracic biopsy with a more favourable safety profile. Trial registration number ClinicalTrials.gov ID: NCT05562895 .
Early Predictors of Surgical Explantation of Transcatheter Aortic Valve Replacement: A Multi-Center International Database Analysis
Bcharah, George , Kumar, Sant, Farina, Juan M., Bcharah, Hend , Abdelnabi, Mahmoud , Sayegh, Jonathan , Ibrahim, Ramzi, Kandil, Omneya , Nabi, Hussein Abdul , Jabri, Ahmad, Naik, Hursh, Yoon, Pyong D., Barrus, Bryan , Sell‐Dottin, Kristen , Farina, Juan M. , Kumar, Sant , Kumar, Sant J , Farina, Juan M , Abdul Nabi, Hussein , Sell-Dottin, Kristen A , Bcharah, Hend , Ibrahim, Ramzi , Barrus, Bryan

Mayo Clinic

Journal of Clinical Medicine | February 16, 2026 | Volume: 15 | Issue: 4 | Pages: 1527

10.3390/jcm15041527 | PMID 41753214 Get It

Background: Indications for TAVR explant have been established, although limited data exist regarding pre-TAVR baseline characteristics that predict eventual explantation. Methods: The TriNetX network, a database comprising medical records from over 105 institutions, was used. Two cohorts were created: those who underwent TAVR without explant and those requiring subsequent TAVR explant and SAVR. Predictors of explantation were analyzed by multivariate models. Results: Among the 63,377 patients undergoing TAVR, 273 (0.4%) required explantation. Patients in the explant group were younger (69.1 ± 11.3 vs. 78.1 ± 8.8 years; p < 0.001), more likely to have a thoracic aortic aneurysm (TAA) (10.6% vs. 4.7%; p < 0.001) and had higher LDL levels (88.2 ± 41.3 vs. 80.7 ± 34.6 mg/dL; p = 0.011). They also had increased post-TAVR rates of acute kidney injury (9.2% vs. 5.2%; p = 0.004) and paravalvular leak (5.9% vs. 0.9%; p < 0.001). Age at TAVR (HR 1.04; CI 1.03–1.06), baseline TAA (HR 1.69; CI 1.09–2.63), history of infective endocarditis (HR 1.92; CI 1.10–3.35), and higher LDL (HR 1.02; 95% CI 1.00–1.03) were independent predictors for explantation. Conclusions: Younger age at TAVR, TAA, history of endocarditis, and elevated baseline LDL were notable predictors of explantation. These findings highlight the necessity of pre-procedural assessment and follow-up in high-risk patients to optimize TAVR durability.
Chromosome X-wide association study in multiple system atrophy identifies sex-differential risk loci
Ray, Anindita , Chia, Ruth , Rasheed, Memoona, Ece, Bayram, Jinhui, Ding, Walton, Ronald L., Diez-Fairen, Monica, Álvarez, Ignacio Morales, Fanciulli, Alessandra , Seppi, Mag Klaus, Duerr, Susanne, Leys, Fabian , Krismer, Florian , Sidoroff, Victoria , Pirker, Walter , Rascol, Olivier, Foubert-Samier, Alexandra, Meissner, Wassilios G, Tison, François , Barone, Paolo, Russillo, Maria Claudia, Marín-Lahoz, Juan, Kulisevsky, J, Torres, Soraya, Mir, Pablo, Periñán, María Teresa, Proukakis, C., Goh, Yee Yen, Parkkinen, Laura, Hu, Michele T, Saxon, Jennifer A. , Rollinson, Sara , Garland, Emily M. , Litvan, Irene, Alcalay, Roy N, Kwei, Kimberly , Lubbe, Steven, Mao, Qinwen, Flanagan, Margaret E, Castellani, Rudolph J, Ndayisaba, Alain , Calvo, Andrea, Canosa, Antonio, Bohannan, Ryan C., Norcliffe-Kaufmann, Lucy, Palma, Jose-Alberto, Dawson, Ted M, Albert, Marilyn S, Pletniková, Olga , Troncoso, Juan C, Lage, Carmen , Sánchez-Juan, Pascual, Serrano, Geidy E, Beach, Thomas G, Morris, Huw R, Clarimon, Jordi, Jaunmuktane, Zane, Révész, Tamás, Warner, Tom, Hardy, John A, Ryten, Mina, Ferrucci, Luigi, Topol, Eric, Torkamani, Ali, DeCasien, Alex R, Chiò, Adriano, Low, Philip, Wszolek, Zbigniew K, Dickson, Dennis W., Traynor, Bryan J, Gibbs, J Raphael, Dalgard, Clifton L, Ross, Owen A, Houlden, Henry, Scholz, Sonja W., Hardy, John , Dickson, Dennis W. , Ross, Owen A. , Houlden, Henry , Scholz, Sonja W. , Chia, Ruth , Proukakis, Christos , Dickson, Dennis W , Dalgard, Clifton L , Ross, Owen A , Houlden, Henry , Scholz, Sonja W , Hardy, John , Reynolds, Regina H. , Díez-Fairén, Mónica , Fanciulli, Alessandra , Stefanova, Nadia , Seppi, Klaus , Krismer, Florian, Zimprich, Alexander , Rascol, Olivier , Foubert‐Samier, Alexandra , Meissner, Wassilios G. , Tison, François , Traon, Anne Pavy‐Le , Pellecchia, Maria Teresa , Marín‐Lahoz, Juan , Kulisevsky, Jaime , Mir, Pablo , Chelban, Viorica , Wu, Lesley , Kobylecki, Christopher , Biaggioni, Italo , Litvan, Irene , Rubio, Ileana, Lubbe, Steven , Flanagan, Margaret E , Castellani, Rudolph J. , Khurana, Vikram , Mora, Gabriele , Floris, Gianluca , Moore, Anni K. , Norcliffe‐Kaufmann, Lucy , Palma, Jose-Alberto , Kaufmann, Horacio , Dawson, Ted M , Rosenthal, Liana S. , Pantelyat, Alexander , Troncoso, Juan C. , Infante, Jon , Serrano, Geidy E. , Beach, Thomas G. , Pástor, Pau , Albani, Diego , Clarimón, Jordi , Jaunmuktane, Zane , Frontzek, Karl , Warner, Thomas T. , Ferrucci, Luigi , Topol, Eric J. , Torkamani, Ali , DeCasien, Alex R. , Chiò, Adriano , Singer, Wolfgang , Cheshire, William P. , Wszołek, Zbigniew K. , Traynor, Bryan J. , Gibbs, J. Raphael

Mayo Clinic

Brain | February 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/brain/awag062 | PMID 41684229 Get It

Abstract The human X chromosome accounts for ∼5% of the genome. Despite its size, the role of X-chromosomal variants in human diseases is not well understood, mainly due to its distinct inheritance pattern and the frequent omission of sex chromosomes from genome-wide association studies. This study used whole-genome sequencing data from 888 multiple system atrophy (MSA) cases and 7128 controls to perform an X-chromosome-wide common variant association study. Our analyses revealed two sex-differential risk loci: one located at Xq28, associated with increased risk for MSA in females [index variant: rs4898389, odds ratio (OR) = 1.69, 95% confidence interval (CI) = 1.40–2.03, P-value = 2.43 × 10⁻⁸], and another at Xp22.2 within the TBL1X gene, identified in males (index variant: rs6638956, OR = 1.48, 95%CI = 1.26–1.73, P-value = 9.92 × 10⁻⁷). In the Xq28 locus, colocalization analyses pointed to FAM3A and PLXNA3 as genes of interest. These findings emphasize the vital role of sex-differential genetic factors in the pathogenesis of MSA.
PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome
Beck, David B. , Heiblig, Maël , Savic, S., Ferrada, Marcela A. , Mekinian, Arsène, Chowdhury, Onima , Hammond, Danielle E., Weeks, Lachelle D., Gurnari, Carmelo , Kirino, Yohei , Georgin-Lavialle, Sophie, Buckley, Sarah A., Garcha, Raman, Harder, Bryan G., Harder, Bryan , Weeks, Lachelle D. , Mékinian, A. , Savic, Sinisa , Hammond, Danielle , Georgin‐Lavialle, Sophie , Savic, Sinisa , Mékinian, Arsène , Hammond, Danielle , Weeks, Lachelle Dawn , Georgin-Lavialle, Sophie , Buckley, Sarah A , Harder, Bryan G , Koster, Matthew J , Gurnari, Carmelo , Kirino, Yohei , Heiblig, Mael , Ferrada, Marcela A , Koster, Matthew J.

Mayo Clinic

Journal of Clinical Medicine | February 11, 2026 | Volume: 15 | Issue: 4 | Pages: 1426

10.3390/jcm15041426 | PMID 41753113 Get It

VEXAS (Vacuoles, E1 ubiquitin-activating enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a systemic disorder characterized by an overlap of hematologic and inflammatory features. Most patients require chronic use of moderate-to-high doses of glucocorticoids (GCs) to maintain disease control. Data on GC-sparing therapies is limited, and there have been no prospective pharmacotherapeutic trials in VEXAS syndrome published to date. Pacritinib, an oral inhibitor of IRAK1, JAK2, and ACVR1, has emerged as a promising therapeutic option for VEXAS syndrome. The PAXIS trial is the first prospective, randomized pharmacotherapeutic study conducted in this rare and severe disease. Utilizing a novel study design and disease-specific endpoints, the trial will evaluate the efficacy and safety of two dose levels of pacritinib compared with placebo in patients with VEXAS syndrome (NCT06782373, EUCTR: 2024-516347-41-00).
Human and viral whole genome sequencing identify HPV and APOBEC as oncogenic drivers in sinonasal squamous cell carcinoma
Zaręba, Łukasz , Eldfors, Samuli , Bryan, Michael , Faquin, William C, Mirabello, Lisa J, Lewis, James S., Faden, Daniel L. , Bryan, Michael E , Faden, Daniel , Lin, Maoxuan , Faquin, William C , Mirabello, Lisa J. , Mishra, Sambit K. , Lewis, James S., Lawrence, Michael S.

Mayo Clinic

No container title available | February 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.04.26345593 | PMID 41728314 Get It

Abstract Sinonasal squamous cell carcinoma (SNSCC) is an aggressive head and neck cancer of the sinonasal cavity which has not benefitted from therapeutic advances over decades 1 . Though historically attributed to inhaled carcinogens such as hardwood dust and tobacco smoking 2 , SNSCC is incidentally associated with human papillomavirus (HPV) 3,4 . Importantly, HPV is the primary oncogenic driver of >80% of anatomically adjacent oropharyngeal cancers 5 . While viral status drives clinical staging and treatment guidelines in these malignancies 6,7 , the potentially oncogenic consequences and prognostic value of host–virus interactions in SNSCC remain incompletely defined. Here, through paired host and viral whole-genome sequencing (WGS), we map the genomic footprint of HPV in SNSCC. Strikingly, lesser studied strains such as HPV45, 51, and 39 constitute driver infections in this rare but clinically credentialed cancer, where extrachromosomal DNA (ecDNA)-associated viral integration and APOBEC mutagenesis are shown to underpin somatic tumor evolution. Statement of Significance Paired host viral and whole-genome sequencing of SNSCC nominates HPV as a primary oncogenic driver of SNSCC. HPV–human ecDNA amplicons harboring noncanonical strains such as HPV45, 51 mediate viral carcinogenesis. Routine clinical diagnostic HPV panels should be expanded to capture the activity of lesser studied strains.
The time course of exercise-induced expiratory and inspiratory muscle fatigue
Hardy, Tim A. , Chadwick, Matt R., Ferguson, Carrie , Cross, Troy J., Cross, Troy J. , Cross, Troy James , Taylor, Bryan J , Taylor, Bryan J.

Mayo Clinic

Journal of Applied Physiology | January 31, 2026 | Volume: 140 | Issue: 2 | Pages: 606-617

10.1152/japplphysiol.00852.2025 | PMID 41617217 Get It

During severe exercise, expiratory and inspiratory muscle fatigue develops by ∼50% of the tolerable exercise duration. The magnitude of expiratory and inspiratory muscle fatigue increases progressively toward exercise intolerance but is not different between muscle groups; this is despite the expiratory muscles being less fatigue-resistant. Inspecting esophageal and gastric twitches via cervical stimulation, we speculate that the progressive magnitude of exercise-induced inspiratory muscle fatigue is a function of recruitment and fatigue of the accessory inspiratory muscles.
Recommendations for Advanced Practice Provider Postgraduate Training Programs in the United States: A Work Product of the Advanced Practice Provider Postgraduate Training Task Force of the Society of Critical Care Medicine
Ricker, Melissa, Abide, Aimee, Bakshi, Vishal, Bane, Tina, Bhullar, Simrit K., Byrd, Cindy , Fuller, Todd E., Gunville, Cameron, Hogan, Brett , Nugent, Katherine Lyn, Pandya, Komal , Peacock, Sarah, Pisa, Michael, Meissen, Heather H., McLaughlin, Diane , Boling, Bryan , Farley, Thomas, Newman, Christopher, Nugent, Katherine Lyn, Peacock, Sarah, Meissen, Heather

Mayo Clinic

Critical Care Medicine | January 30, 2026 | Volume: 54 | Issue: 4 | Pages: 825-835

10.1097/ccm.0000000000007061 | PMID 41615242 Get It

OBJECTIVES: The overall goal of this work is to discuss the various topics associated with critical care advanced practice provider (APP) postgraduate training programs and provide resources for new, developing and existing programs. DESIGN: Three rounds of voting until consensus achieved. SETTING: Electronic surveys, followed by virtual meeting. SUBJECTS: Critical care APPs, physicians, a pharmacist, and a nurse were also included to ensure multidisciplinary representation. All subjects resided and practiced in the United States with a history of education scholarship or post-graduate training leadership. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The workgroup included 14 APPs (ten nurse practitioners and four physician associates), three physicians, one pharmacist, and one registered nurse from 14 institutions across the United States. The workgroup identified six areas of concentration: administration, audience, program structure, curriculum, procedural competence, and accreditation. A survey was generated and employed in three rounds. The first two rounds of voting were completed anonymously, the third round was completed as a live meeting until consensus recommendations, defined as 75% agreement or more, were achieved. CONCLUSIONS: Expert consensus was used to generate consensus recommendations for critical care postgraduate training programs based upon 3 rounds of voting.
Abstract DP352: White Matter Hyperintensity Burden, APOE4 and Amyloid-PET Relationship in Cognitively Normal Individuals
Saidi, Pouria , Woodruff, Bryan K. , Rj, Caselli, Baxter, Leslie, Dumitrascu, Oana, Dumkrieger, Gina , Cramer, Justin , Caselli, Richard J. , Baxter, Leslie

Mayo Clinic

Stroke | January 29, 2026 | Volume: 57 | Issue: Suppl_1 | Pages: No page available

10.1161/str.57.suppl_1.dp352 Get It

Introduction: Emerging evidence highlights the increased white matter hyperintensity (WMH) burden in APOE4 homozygotes, the greatest genetic risk factor for late-onset Alzheimer's disease (AD). The link between WMH and cerebral amyloid-beta (Aβ) accumulation remains unclear, especially in presymptomatic AD phases. We aimed to determine whether WMH burden (global or regional) mediates the association between APOE4 homozygosity and amyloid-PET Aβ deposition in a population of subjects with intact cognition. Methods: WMH were segmented using a deep learning model applied to T1 and T2-FLAIR MRI scans from 49 cognitively intact individuals older than 50. The global and regional (periventricular, lobar, basal ganglia, infratentorial) WMH volumes were adjusted for total intracranial volume and log-transformed to normalize distribution. Amyloid-PET cerebral Aβ burden was quantified in centiloid units; individuals with centiloid > 20 were classified as Aβ-positive. To examine our mediation hypothesis, we tested three pathways using logistic and linear regression models: 1) Path a, the association between APOE4 and global or regional WMH volumes (outcome); 2) Path b, the association between WMH volumes and Aβ positivity (outcome); 3) Path c (total) and c' (direct) effects of APOE4on Aβ positivity (outcome), before and after adjusting for WMH volumes. All models incorporated age and vascular risk factors (hypertension, diabetes, hypercholesterolemia, cigarette smoking). Results: We included 11 APOE4 homozygotes, of whom 7 were Aβ-positive and 38 non-carriers (35 3/3 and 3 3/2) (6 Aβ-positive). Compared to APOE4 non-carriers, APOE4 homozygotes had significantly greater WMH volumes in the posterior periventricular region only (p= 0.0453) (path a). Homozygotes were significantly more likely to be Aβ-positive compared to non-carriers (total effect, path c p=0.0019). This association remained significant after adjusting for WMH (direct effect, path c'= 0.0027). However, neither global (p=0.72) nor posterior periventricular (p=0.84) WMH volumes predicted Aβ positivity (path b) (Figure). Conclusions: In our cohort of cognitively normal individuals including preclinical AD, neither global nor regional WMH burden mediated the relationship between APOE4 homozygosity and Aβ positivity. Larger studies are needed to further evaluate the mechanistic relationship between WMH and neurodegeneration in APOE4 carriers.
From first generation to the next: evolution and research trends in iStent technology
Ang, Bryan Chin Hou, Wong, Natalie Shi Qi , Lim, Sheng Yang , Ang, Bryan C H , Betzler, Bjorn Kaijun

Mayo Clinic

Frontiers in Medicine | January 23, 2026 | Volume: 12 | Issue: No issue available | Pages: No page available

10.3389/fmed.2025.1724886 | PMID 41657563 Get It

The iStent series constitutes a range of trabecular bypass minimally invasive glaucoma surgery (MIGS) devices, which offers intraocular pressure (IOP) reduction with favourable safety profiles, in patients with open-angle glaucoma (OAG). Having undergone significant evolution since its initial US FDA-approval in 2012, successive generations address previous limitations, while enhancing IOP-lowering efficacy through device and delivery system design iterations. Longer-term and real-world iStent data demonstrate the durability of IOP- and medication-lowering outcomes with minimal complications, while preliminary studies across a wider spectrum of glaucoma subtypes and severities provide limited evidence of successful outcomes beyond mild-to-moderate OAG, both with and without concomitant cataract surgery. Aqueous humour outflow assessment and novel intra-operative techniques may further facilitate more accurate and effective iStent positioning. Despite typically higher upfront costs, results from both cost-effectiveness and patient-reported outcome studies are encouraging. Combination MIGS with the iStent, leveraging on the multiple mechanisms of actions of various procedures, may provide greater IOP-lowering efficacy without compromising safety. With expanding clinical data and progressive enhancements, iStent technology is likely to remain a key component of the evolving MIGS landscape.
Regulatory T-cell Sensing of Extracellular ATP via P2RX7 Promotes Their Accumulation and Suppression and Drives Lung Tumor Growth
Santiago-Carvalho, Igor , Francisco, Ronaldo da Silva , Macedo, Bruna de Gois , Salgado, Caio Loureiro , Stoll, Carly R. , Shao, Samantha C. , Beniwal, Angad , Kwok, Tina , Banuelos, Alma , Cione, Marcos Pinheiro , White, Emily , Johnston, Tyler, Leff, Chloe , Silva-Junior, Ildefonso , Souza, Fabio Carvalho de, Thant, Win , Fernandez-Bussy, Sebastian, Abia-Trujillo, David, Vu, Linh H, Husta, Bryan C, Copland, John A. , Gounari, Fotini , Justilien, Verline , Cione, Marcos Vinícios Pinheiro , Francisco, Ronaldo , Macedo, Bruna Gois , Johnston, Tyler M , Leff, Chloe Liliana , Carvalho de Souza, Fabio , Pandya, Prita , D'Império Lima, Maria Regina , Fernandez-Bussy, Sebastian , Abia-Trujillo, David , Vu, Linh H , Tran, Nhan L , Husta, Bryan C , Copland, John A , Gounari, Fotini , Justilien, Verline , Lancaster, Jessica N , Borges da Silva, Henrique , Silva, Ildefonso , Pandya, Prita , Lima, Maria Regina D’Império , Tran, Nhan L. , Lancaster, Jessica N. , Silva, Henrique Borges da

Mayo Clinic

Cancer Immunology Research | January 21, 2026 | Volume: 14 | Issue: 4 | Pages: 658-675

10.1158/2326-6066.cir-25-0567 | PMID 41564348 Get It

Abstract Lung cancer is the leading cause of cancer-related deaths worldwide, and despite advances in treatment, immune suppression remains an obstacle to effective therapy. Effector CD4+ T cells (CD4+ Teff) are critical for antitumor immunity, but their function is often inhibited by regulatory T cells (Treg), which accumulate in lung tumors and mediate suppressive functions through multiple mechanisms. This suppression leads to tumor progression and poor patient outcomes. However, the mechanisms underlying Treg-mediated suppression are not fully understood. Herein, we identify the extracellular adenosine 5-triphosphate receptor P2RX7 as a key regulator of Treg function in lung tumors. In a murine lung cancer model induced by Lewis lung carcinoma cells, we found that P2RX7 enhanced the suppressive capacity of tumor-infiltrating Tregs, promoting tumor growth. In T cell–specific P2RX7-knockout (P2RX7-KO) mice, reduced Treg infiltration was accompanied by increased CD4+ Teff accumulation and improved tumor control. Treg-specific P2RX7-KO mice exhibited reduced tumor growth, confirming a Treg-intrinsic role of P2RX7. Suppression assays revealed that tumor-infiltrating wild-type Tregs had greater suppressive activity compared with P2RX7-KO Tregs, which failed to inhibit type 1 and follicular helper T–like responses. This was associated with increased tumor-specific IgG production by lung B cells in P2RX7-KO mice. We also observed that wild-type Tregs expressed higher levels of the immunosuppressive molecule CTLA-4 when compared with P2RX7-KO Tregs. Thus, we conclude that P2RX7 expression on Tregs is essential for their suppressive function in lung cancer and targeting P2RX7 may constitute a strategy to improve lung cancer treatment by alleviating Treg-mediated immune suppression.